Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Bill Tomko who wrote (351)	6/6/2000 1:26:00 PM
From: tuck	Respond to of 496

Bill, I don't think anyone asked me for my thoughts, recently, but since you addressed it to me: check replies 322 - 330 if you care about my thoughts, which haven't changed much. Perhaps the real problem is AMGEN management, as it seems to me they dragged their feet on getting GLFD neurotrophins into the clinic. Not much GLFD could do about that, so maybe I'm being a little unfair to GLFD management. It must of looked like a sweet deal when they made it, and maybe it still is. Some SI posters with strong scientific backgrounds were in GLIA, too. I look forward to their comments re GLFD's neurotrophins taking share from similar drugs already out there. It could be that folks who look positioned to be 1st to market (such as NEOT) will suffer PIII failures while GLFD doesn't, but I'm not banking on that. Cheers, Tuck